

Synthetic approaches to komarovispiranes. Enantiospecific synthesis of bicyclo[3.3.0]octanespiro[3.1']cyclohexanes

A. Srikrishna* and B. Beeraiah

Department of Organic Chemistry, Indian Institute of Science, Bangalore 560 012, India

Received 7 December 2006; revised 21 January 2007; accepted 31 January 2007


Available online 3 February 2007

Abstract—A ring-closing metathesis based spiroannulation of cyclopentane and cyclohexanes at the C-3 carbon atom of a bicyclo[3.3.0]octane, as a model study directed towards the enantiospecific synthesis of the novel diterpenes komarovispiranes, is described.

© 2007 Elsevier Ltd. All rights reserved.


Dracocephalum komarovi Lipsky is a perennial semi-shrub in Uzbekistan, and its extract is known to treat various diseases such as inflammatory diseases and hypertony. Initial phytochemical investigations on the whole plants of *D. komarovi* by Honda and co-workers led to the isolation¹ of komaroviquinone **1**, which belongs to the icetexane group of diterpenes. Further investigations led to the isolation² of a novel tricyclic diterpene komarovispirone **2** containing a new and interesting cyclohexane spirofused to a hydrindane carbon framework **3**, komarovispirane. Both komaroviquinone **1** and komarovispirone **2** were found to exhibit trypanocidal activity against the epimastigotes *Trypanosoma cruzi*, the causative agent of American trypanosomiasis. The novel structure containing an unusual carbon framework coupled with the biological activity have made komarovispirone **2** and its analogues interesting synthetic targets. So far there is no report in the literature on either the total synthesis or model studies of komarovispiranes.

Recently, we reported³ an efficient method for the enantiospecific generation of bicyclo[3.3.0]octanone **4** starting from campholenaldehyde **5** employing an intramolecular rhodium carbenoid CH insertion reaction. It was contemplated that bicyclic ketone **4** is an ideal substrate to elaborate into komarovispiranes **3**, which requires spiroannulation of a cyclohexane ring at the C-3 carbon and expansion of the second cyclopentane ring into a cyclohexane ring, **Scheme 1**. As a model




study, we first investigated the spiroannulation of a cyclohexane to bicyclic ketone **4**, which is the subject of this letter.

A ring-closing metathesis (RCM)⁴ based strategy was considered for the spiroannulation of the six membered ring. For the creation of the requisite spiro centre, a



Scheme 1.

* Corresponding author. Tel.: +91 80 22932215; fax: +91 80 23600529; e-mail: ask@orgchem.iisc.ernet.in




Scheme 2. Reagents, conditions and yields: (a) $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{CO}_2\text{Et}$, NaH, THF, $0^\circ\text{C}\rightarrow\text{reflux}$, 4 h; (b) LAH, Et_2O , -70°C , 2 h; (c) $\text{CH}_3\text{C}(\text{OEt})_3$, EtCO_2H (catalytic), sealed tube, 180°C , 60 h.

Claisen rearrangement of allyl alcohol **6** was conceived, **Scheme 2**. Synthesis of the bicyclic ketone **4** has been accomplished as reported earlier.³ Horner–Wadsworth–Emmons reaction of bicyclic ketone **4** with triethyl phosphonoacetate and sodium hydride in refluxing THF furnished an $\sim 3:2$ *E,Z* mixture of α,β -unsaturated ester **7** in 88% yield,⁵ which on reduction with lithium aluminium hydride (LAH) in ether at low temperature generated, regioselectively, allyl alcohol **6** in 94% yield. Johnson's orthoester variant⁶ of the Claisen rearrangement was chosen for creation of the quaternary carbon atom. Thus, thermal activation of a mixture of allyl alcohol **6** and triethyl orthoacetate in the presence of a catalytic amount of propionic acid in a sealed tube at 180°C for 60 h furnished a 4:1 diastereomeric mixture of acetates **8a** and **8b**, which were separated by column chromatography on silver nitrate impregnated silica gel.⁸ The stereochemistry of acetates **8a** and **8b** were assigned on the basis of the preferred geometry in the transition state during the Claisen rearrangement.


To test the feasibility of the RCM strategy, initially spiroannulation of a cyclopentane ring was investigated via the RCM reaction of hydroxydiene **9**, **Scheme 3**.

Accordingly, the ester group in **8a** was transformed into the corresponding aldehyde by a two-step reduction–oxidation protocol to furnish aldehyde **10** in 91% overall yield. Grignard reaction of aldehyde **10** with vinylmagnesium bromide in THF furnished hydroxydiene **9** in 96% yield. RCM reaction of hydroxydiene **9** with Grubbs' first generation catalyst $[\text{Cl}_2\text{Ru}(\text{PCy}_3)_2=\text{CHPh}]$ in methylene chloride at room temperature for 10 min quantitatively furnished spiro alcohol **11**, which on oxidation with pyridinium chlorochromate (PCC) and silica gel in methylene chloride gave spiroenone **12** in near quantitative yield. The structure of spiroenone **12** was established from its spectral data.⁸

After successfully accomplishing the spirocyclopentannulation, the strategy was extended to the spirocyclohexannulation. Thus, sonochemically accelerated Barbier reaction of aldehyde **10** with zinc and allyl bromide in THF furnished hydroxydiene **13** in 94% yield. RCM reaction of hydroxydiene **13** with Grubbs' first generation catalyst in methylene chloride at room temperature furnished spiro alcohol **14** in 88% yield. Oxidation of homoallyl alcohol **14** with PCC and silica gel in methylene chloride generated ketone **15** in 95% yield, whose structure was established from its spectral data.⁸



Scheme 3. Reagents, conditions and yields: (a) (i) LAH, Et_2O , 0°C , 2 h; (ii) PCC, silica gel, CH_2Cl_2 , rt, 40 min; (b) $\text{CH}_2=\text{CHMgBr}$, THF, 0°C , 0.5 h; (c) $\text{Cl}_2\text{Ru}(\text{PCy}_3)_2=\text{CHPh}$ (5 mol %), CH_2Cl_2 , rt, 10 min; (d) PCC, silica gel, CH_2Cl_2 , rt, 3 h; (e) $\text{CH}_2=\text{CHCH}_2\text{Br}$, Zn, THF,), 0.5 h; (f) $\text{Cl}_2\text{Ru}(\text{PCy}_3)_2=\text{CHPh}$ (5 mol %), CH_2Cl_2 , rt, 32 h.



Scheme 4. Reagents, conditions and yields: (a) 5% NaOH, MeOH–H₂O (1:1), reflux, 4 h; (b) (i) (COCl)₂, C₆H₆, rt, 2 h; (ii) CH₂N₂, Et₂O, 0 °C, 3 h; (c) hν, MeOH, 1 h; (d) (i) LAH, Et₂O, 0 °C, 2 h; (ii) PCC, NaOAc, CH₂Cl₂, rt, 40 min; (e) CH₂=CHMgBr, THF, 0 °C, 0.5 h; (f) Grubbs' II generation catalyst (5 mol %), CH₂Cl₂, rt, 5 h; (g) PCC, silica gel, CH₂Cl₂, rt, 3 h; (h) *i*-PrMgBr, THF, 0 °C, 0.5 h; (i) PCC, NaOAc, CH₂Cl₂, rt, 4 h.

Spirocyclohexannulation was also investigated via homologation of ester **8a** for the synthesis of a bisnorkomarospirane, (Scheme 4). Thus, hydrolysis of ester **8a** with sodium hydroxide in aqueous methanol furnished acid **16**. The reaction of acid **16** with oxalyl chloride in benzene followed by treatment of the resultant acid chloride with an excess of ethereal diazomethane furnished diazoketone **17**. Photochemical reaction of diazoketone **17** in methanol using a 450 W Hanovia medium pressure mercury vapor lamp furnished the homologated ester **18** in 86% yield. Ester **18** was then converted into aldehyde **19** in 84% yield by a reduction–oxidation protocol. Grignard reaction of aldehyde **19** with vinylmagnesium bromide in THF furnished hydroxydiene **20** in 96% yield. As the RCM reaction of hydroxydiene **20** with Grubbs' first generation catalyst was slow and inefficient, reaction was instead carried out with Grubbs' second generation catalyst. Thus, RCM of hydroxydiene **20** with 5 mol % of Grubbs' second generation catalyst in methylene chloride at room temperature for 5 h furnished the spiro alcohol **21** in 91% yield, which on oxidation with PCC and silica gel in methylene chloride gave spiroenone **22** in 94% yield.⁸ An alkylative 1,3-enone transposition method⁷ was employed for the conversion of spiroenone **22** into a bisnorkomarospirane. The reaction of spiroenone **22** with isopropylmagnesium bromide in THF gave allyl alcohol **23**, which on oxidation with PCC and sodium acetate in methylene chloride furnished bisnorkomarospirane **24** in 84% yield (over two steps).⁸

In conclusion, we have developed a convenient and efficient Claisen rearrangement–RCM reaction-based methodology for spirocyclopentane and spirocyclohexane annulation of bicyclic ketone **4** and applied it in the synthesis of a bisnorkomarospirane. Extension of the strategy for the enantiospecific synthesis of a komarospirane is currently under investigation.

Acknowledgement

We thank the Council of Scientific and Industrial Research, New Delhi, for the award of a research fellowship to B.B. We are grateful to Organica Aromatics (Bangalore) Pvt. Ltd. for the generous gift of campholenaldehyde.

References and notes

- Uchiyama, N.; Kiuchi, F.; Ito, M.; Honda, G.; Takeda, Y.; Khodzimatov, O. K.; Ashurmetov, O. A. *J. Nat. Prod.* **2003**, *66*, 128; For synthesis, see: Sengupta, S.; Drew, M. G. B.; Mukhopadhyay, R.; Achari, B.; Banerjee, A. K. *J. Org. Chem.* **2005**, *70*, 7694.
- Uchiyama, N.; Ito, M.; Kiuchi, F.; Honda, G.; Takeda, Y.; Khodzimatov, O. K.; Ashurmetov, O. A. *Tetrahedron Lett.* **2004**, *45*, 531; Uchiyama, N.; Kiuchi, F.; Ito, M.; Honda, G.; Takeda, Y.; Khodzimatov, O. K.; Ashurmetov, O. A. *Tetrahedron* **2006**, *62*, 4355.
- Srikrishna, A.; Beeraiah, B.; Satyanarayana, G. *Tetrahedron: Asymmetry* **2006**, *17*, 1544.
- (a) Grubbs, R. H.; Chang, S. *Tetrahedron* **1998**, *54*, 4413; (b) Fürstner, A. *Angew. Chem., Int. Ed.* **2000**, *39*, 3013; (c) Trnka, T. M.; Grubbs, R. H. *Acc. Chem. Res.* **2001**, *34*, 18; (d) Grubbs, R. H. In *Handbook of Metathesis*; Wiley-VCH, 2003; Vol. 2.
- No attempt was made to separate and assign the structures of the *E* and *Z* isomers of **7** as both isomers lead to same product after Claisen rearrangement of the alcohol **6**.
- Johnson, W. S.; Werthemann, L.; Bartlett, W. R.; Brockson, T. J.; Li, T. T.; Faulkner, D. J.; Petersen, M. R. *J. Am. Chem. Soc.* **1970**, *92*, 741.
- Buchi, G.; Egger, B. *J. Org. Chem.* **1971**, *36*, 2021.
- Yields refer to isolated and chromatographically pure compounds. All the compounds exhibited spectral data (IR, ¹H and ¹³C NMR and mass) consistent with their structures. Selected spectral data ethyl 2-[(1*R*,3*R*,5*R*)-7,8,

8-trimethyl-3-vinylbicyclo[3.3.0]octa-6-en-3-yl]acetate **8a**: $[\alpha]_D^{26} -16.5$ (*c* 2.0, CHCl₃); IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1737, 1638, 912; ¹H NMR (300 MHz, CDCl₃ + CCl₄): δ 5.97 (1H, dd, *J* 17.4 and 10.8 Hz), 5.06 (1H, br s), 4.95 (1H, dd, *J* 17.4 and 0.9 Hz), 4.90 (1H, dd, *J* 10.8 and 0.9 Hz), 4.08 (2H, q, *J* 7.2 Hz, OC H₂CH₃), 3.06–3.14 (1H, m), 2.34 (1H, t of d, *J* 12.0 and 7.2 Hz), 2.43 (2H, s), 2.01 (1H, ddd, *J* 12.6, 8.7 and 2.1 Hz), 1.72 (1H, ddd, *J* 12.6, 6.9 and 1.8 Hz), 1.56 (3H, s), 1.43 (1H, t, *J* 12.0 Hz), 1.35–1.25 (1H, m), 1.24 (3H, t, *J* 7.2 Hz), 1.02 (3H, s), 0.96 (3H, s); ¹³C NMR (75 MHz, CDCl₃ + CCl₄): δ 171.4 (C), 144.9 (CH), 144.6 (C), 127.4 (CH), 111.3 (CH₂), 59.7 (CH₂), 53.4 (CH), 49.3 (C), 46.8 (C), 45.0 (CH), 42.7 (CH₂), 42.1 (CH₂), 38.3 (CH₂), 29.4 (CH₃), 21.6 (CH₃), 14.4 (CH₃), 12.4 (CH₃); HRMS: *m/z* calcd for C₁₇H₂₆O₂Na (M+Na): 285.1830. Found: 285.1830. For ethyl 2-[(1*R*,3*S*,5*R*)-7,8,8-trimethyl-3-vinylbicyclo[3.3.0]octa-6-en-3-yl]acetate **8b**: $[\alpha]_D^{26} -7.4$ (*c* 5.0, CHCl₃); IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1738, 1637, 912; ¹H NMR (300 MHz, CDCl₃ + CCl₄): δ 5.76 (1H, dd, *J* 17.4 and 10.8 Hz), 5.06 (1H, br s), 5.02 (1H, d, *J* 10.8 Hz), 4.97 (1H, d, *J* 17.4 Hz), 4.06 (2H, q, *J* 7.2 Hz, OCH₂CH₃), 3.00–2.98 (1H, m), 2.41 and 2.33 (2H, 2 × d, *J* 13.8 Hz), 2.30–2.10 (2H, m), 1.68 (1H, ddd, *J* 12.3, 7.2 and 1.8 Hz), 1.54 (3H, s), 1.45–1.24 (2H, m), 1.22 (3H, t, *J* 7.2 Hz), 0.97 (3H, s), 0.94 (3H, s); ¹³C NMR (75 MHz, CDCl₃ + CCl₄): δ 171.4 (C), 144.7 (C), 144.0 (CH), 127.7 (CH), 112.7 (CH₂), 59.8 (CH₂), 53.5 (CH), 48.7 (C), 46.6 (C), 46.1 (CH₂), 45.5 (CH), 41.4 (CH₂), 40.0 (CH₂), 29.3 (CH₃), 21.7 (CH₃), 14.5 (CH₃), 12.5 (CH₃); HRMS: *m/z* calcd for C₁₇H₂₆O₂Na (M+Na) 285.1830. Found: 285.1821. For (1*R*,3*R*,5*R*)-7,8,8-trimethylbicyclo[3.3.0]octanespiro[3.1']cyclopentane-6,4'-dien-3'-one **12**: $[\alpha]_D^{26} -14.0$ (*c* 2.0, CHCl₃); IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1717, 1586; ¹H NMR (300 MHz, CDCl₃ + CCl₄): δ 7.42 and 6.02 (2H, 2 × d, *J* 5.4 Hz), 5.01 (1H, br s), 3.25–3.05 (1H, m), 2.40–2.30 (1H, m), 2.19 (2H, s), 1.80–1.30 (4H, m), 1.58 (3H, s), 1.03 (3H, s), 0.96 (3H, s); ¹³C NMR (75 MHz, CDCl₃ + CCl₄): δ 208.4 (C), 171.3 (CH), 145.2 (C), 132.5 (CH), 127.1 (CH), 55.6 (CH), 53.8 (C), 49.1 (CH₂), 46.8 (C), 46.1 (CH), 44.6 (CH₂), 41.1 (CH₂), 29.2 (CH₃), 21.6 (CH₃),

12.4 (CH₃); HRMS: *m/z* calcd for C₁₅H₂₀ONa (M+Na): 239.1412. Found: 239.1413. For (1*R*,3*R*,5*R*)-7,8,8-trimethylbicyclo[3.3.0]octanespiro[3.1']cyclohexane-6,5'-dien-3'-one **15**: $[\alpha]_D^{26} -19.4$ (*c* 1.8, CHCl₃); IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1718; ¹H NMR (300 MHz, CDCl₃ + CCl₄): δ 5.70–5.55 (2H, m), 4.98 (1H, br s), 3.20–3.05 (1H, m), 2.80 (2H, s), 2.50–2.35 (1H, m), 2.40 (2H, s), 1.81 (1H, dd, *J* 12.9 and 9.0 Hz), 1.56 (3H, s), 1.46 (2H, d, *J* 9.6 Hz), 1.30 (1H, dd, *J* 12.9 and 6.3 Hz), 1.00 (3H, s), 0.93 (3H, s); ¹³C NMR (75 MHz, CDCl₃ + CCl₄): δ 208.6 (C), 144.9 (C), 137.6 (CH), 127.4 (CH), 122.3 (CH), 53.9 (CH), 50.2 (CH₂), 49.9 (C), 46.8 (C), 45.5 (CH), 44.5 (CH₂), 41.3 (CH₂), 39.7 (CH₂), 29.2 (CH₃), 21.6 (CH₃), 12.5 (CH₃); HRMS: *m/z* calcd for C₁₆H₂₂OK (M+K): 269.1308. Found: 269.1327. For (1*R*,3*R*,5*R*)-7,8,8-trimethylbicyclo[3.3.0]octanespiro[3.1']cyclohexane-6,2'-dien-4'-one **22**: $[\alpha]_D^{26} -12.5$ (*c* 1.2, CHCl₃); IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1682; ¹H NMR (300 MHz, CDCl₃ + CCl₄): δ 6.61 (1H, d, *J* 9.9 Hz), 5.82 (1H, d, *J* 9.9 Hz), 5.10 (1H, br s), 3.22–3.10 (1H, m), 2.46 (1H, dt, *J* 11.4 and 7.5 Hz), 2.45–2.30 (2H, m), 2.01 (1H, ddd, *J* 12.6, 8.7 and 1.8 Hz), 1.95–1.85 (2H, m), 1.58 (3H, t, *J* 1.8 Hz), 1.70–1.55 (1H, m), 1.49 (1H, t, *J* 12.0 Hz), 1.33 (1H, dd, *J* 13.2 and 6.0 Hz), 1.03 (3H, s), 0.97 (3H, s); ¹³C NMR (75 MHz, CDCl₃ + CCl₄): δ 199.2 (C), 159.0 (CH), 145.2 (C), 127.8 (CH), 127.3 (CH), 54.6 (CH), 46.9 (C), 45.9 (C), 45.8 (CH), 42.4 (CH₂), 40.3 (CH₂), 34.6 (CH₂), 32.6 (CH₂), 29.3 (CH₃), 21.6 (CH₃), 12.5 (CH₃). For (1*R*,3*R*,5*R*)-4'-isopropyl-7,8,8-trimethylbicyclo[3.3.0]octanespiro[3.1']cyclohexane-6,3'-dien-2'-one **24**: $[\alpha]_D^{26} -4.0$ (*c* 1.0, CHCl₃); IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1664, 1628; ¹H NMR (300 MHz, CDCl₃ + CCl₄): δ 5.81 (1H, d, *J* 0.9 Hz), 5.09 (1H, br s), 3.15–3.00 (1H, m), 2.45–2.19 (5H, m), 1.90–1.68 (4H, m), 1.56 (3H, s), 1.52–1.39 (1H, m), 1.11 (6H, d, *J* 6.9 Hz), 1.00 (3H, s), 0.96 (3H, s); ¹³C NMR (75 MHz, CDCl₃ + CCl₄): δ 202.2 (C), 168.3 (C), 144.6 (C), 127.5 (CH), 123.9 (CH), 54.3 (CH), 53.6 (C), 46.9 (C), 45.3 (CH), 38.5 (CH₂), 35.6 (CH), 35.5 (CH₂), 32.1 (CH₂), 29.3 (CH₃), 24.9 (CH₂), 21.6 (CH₃), 20.9 (2 C, CH₃), 12.5 (CH₃); HRMS: *m/z* calcd for C₁₉H₂₉O (M+H): 273.2218. Found: 273.2221.